Infinity Pharmaceuticals Inc. (INFI)
  • Россия
  • Украина

Infinity Pharmaceuticals Inc. (INFI)

Contact Details

780 Memorial Dr, Cambridge, Massachusetts, USA 02139-4613
(617) 453-1000
780 Memorial Dr, Cambridge, Massachusetts, USA 02139-4613

General Information

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

Contact Information

Phone(617) 453-1000
Fax(617) 453-1001
Website 1
Website 2
Website 3
Thomson Reuters PermID4295915855


NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO and President$1,635,4792014-57.6%
CFO and Other Executive Officer$813,4772014-25.4%
Chief Medical Officer$1,709,555201466.9%
Divisional President$1,179,8442014-55.5%
Chief Scientific Officer$801,2262014-55.2%

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
National Institutes of HealthPhysical Sciences - Applied Research/Exploratory DevelopmentAugust 20, 2004$46.8 million
National Institutes of HealthMedical and Surgical Instruments, Equipment and SuppliesJune 15, 2003$57,360

Corporate Data


  • Pharmaceutical Preparation Manufacturing
  • Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

SIC Industries

  • Pharmaceutical Preparations
  • Commercial Physical Research

Company Size

Sales Volume$109 million


Ticker SymbolINFI
ExchangeNASDAQ Global Select Market
Year Founded1995


Previous Close5.78
Bid5.70 x 100
Ask5.77 x 500
Day`s Range5.69 - 5.84
52-Week Range4.95 - 15.27
Average Volume (1M)759,194
Forward P/E13.08x
Market Cap.$295.55 Million
Last Dividend Amount0
1y Target Price Est.15.33


Summary of Form-D Filings

    Filing History

  • Infinity Pharmaceuticals Inc. has filed 1 Form Ds since 2008. Of these filings, 1 has been for a unique offering.
  • Through these filings, they have raised $78,540,191.
  • They have not paid finder`s fees or sales commissions in connection with these offerings.
  • They have not used any of the proceeds from its offerings to pay officers or directors.
  • The types of securities they have issued are Equity.
  • They have relied on the following exemptions in past filings Rule 506.

    Analysis of Past Filings

  • Infinity Pharmaceuticals Inc. has filed 1 fewer filing compared to an average company in the Biotechnology category.
  • They have had about as many unique offerings as an average company in the Biotechnology category.
  • The total amount raised they have raised is 2,398% higher than the average for a company in the Biotechnology category.

Form-D Filings

Filing DateFiling TypeTotal Offering AmountTotal Amount RaisedTotal Remaining For Sale
September 21, 2012New$78,540,191$78,540,191$0


Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue9,08090,7434,8804,363
Cost of Revenue----
Gross Profit9,08090,7434,8804,363
Research Development38,89037,72934,06288,428
Selling General and Administrative9,3519,7549,4108,550
Depreciation and Amortization----
Other Operating Expenses----
Total Operating Expenses48,24147,48343,47296,978
Other Income/Expenses Net----
Earnings Before Interest and Taxes(39,161)43,260(38,592)(92,615)
Interest Expense31131199647
Income Before Tax(39,335)43,024(38,428)(93,302)
Income Tax Expense(145)480--
Minority Interest----
Net Income from Continuing Ops(39,190)42,544(38,428)(93,302)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income(39,190)42,544(38,428)(93,302)
Preferred Stock and Other Adjustments-848--
Net Income Applicable to Common Shares(38,342)41,696(38,428)(93,302)